Tenaya Bets on Veteran CFO to Steer Pivotal Gene Therapy Pipeline

SOUTH SAN FRANCISCO, Calif. – June 29, 2026 – In a move that signals a clear focus on its next phase of growth, clinical-stage biotechnology company Tenaya Therapeutics has appointed Eric Hyllengren as its new Chief Financial Officer. The appointment, effective July 13, 2026, is more than a simple leadership shuffle; it represents a strategic reinforcement of the company's financial command as it prepares to navigate the capital-intensive waters of late-stage clinical trials for its portfolio of heart disease therapies.

Hyllengren will take the financial helm from retiring Senior Vice President of Finance, Hiro Higa, who will remain as a consultant to ensure a smooth transition. For a company like Tenaya, which is advancing a cutting-edge pipeline of genetic medicines, the role of CFO transcends traditional bookkeeping. It requires a strategist who can secure substantial funding, manage a high-cost research and development budget, and articulate a complex scientific story to an exacting financial market. Hyllengren’s background suggests he has been hired to do precisely that.

A Calculated Move for a Critical Juncture

The timing of Hyllengren’s arrival is critical. Tenaya is approaching a series of crucial inflection points for its lead programs, moving them toward pivotal trials that could ultimately lead to commercialization. This transition from an early- to a late-stage clinical company dramatically alters its financial needs and risk profile. While the company's balance sheet reportedly holds more cash than debt, the nature of biotech R&D means it is also, like its peers, rapidly consuming capital to fund its ambitious programs.

Faraz Ali, Tenaya’s Chief Executive Officer, underscored the strategic nature of the hire. “We are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and corporate developments, including a background in the cell and gene therapy space,” he stated. Ali’s emphasis on the “next horizon” and the need to create “long-term value for patients and shareholders” frames Hyllengren’s appointment as a key piece of the company’s long-range plan.

The appointment comes as the company manages a planned leadership change, with the retirement of Hiro Higa after a six-year tenure. Ali praised Higa’s significant contributions, particularly in guiding Tenaya through its initial public offering and establishing its financial infrastructure. The planned overlap and consulting arrangement signal a well-managed transition, a detail often appreciated by investors who value stability.

The Anatomy of a Modern Biotech CFO

In today's fiercely competitive biotech landscape, the CFO role is increasingly specialized. Companies developing novel modalities like gene therapy require financial leaders who are fluent in both capital markets and complex science. Hyllengren’s resume appears tailor-made for this challenge.

With over two decades of experience, his career includes a formative 15-year period at biotech giant Amgen, where he held roles across finance, investor relations, and business development. More recently, he has specialized in steering smaller, clinical-stage companies through financial and organizational transformations. As CFO and COO at Atara Biotherapeutics, a cell therapy company, he was instrumental in executing over $500 million in public financings—a figure that undoubtedly caught the attention of Tenaya’s board. His most recent post as CFO at Zura Bio further solidified his experience in financing clinical development programs.

This deep expertise in biotech finance, particularly within the cell and gene therapy sector, is a valuable commodity. Such leaders are adept at navigating the volatile public markets, securing non-dilutive funding through partnerships, and optimizing capital allocation to give promising therapies the best chance of success. As Hyllengren himself noted, “I look forward to partnering closely with the leadership team to execute on Tenaya’s strategic priorities, optimize capital allocation, and support the advancement of its promising therapies.”

A Pipeline Demanding Robust Financial Stewardship

The strategic importance of Hyllengren’s role becomes clear when looking at Tenaya’s pipeline. The company is not developing simple molecules; it is pioneering potentially curative gene therapies for devastating heart conditions, a field that holds immense promise but also carries enormous development costs.

Its clinical-stage assets include:
* TN-201: A gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), a common inherited heart disease. Recent interim data from the MyPEAK™-1 study has been encouraging, with all six treated patients showing reductions in premature ventricular contractions, a key marker of the disease.
* TN-401: A gene therapy targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), another genetic heart condition. The company has also reported promising early clinical data for this candidate.
* TN-301: A highly specific small molecule inhibitor being developed for broader conditions like heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD), which is described as being “poised to advance.”

Each of these programs represents a significant scientific undertaking that will require tens, if not hundreds, of millions of dollars to see through to regulatory submission. Hyllengren’s primary challenge will be to ensure the financial runway is long enough to reach key data readouts and value-creation milestones, thereby attracting the further investment needed to get these therapies to patients.

Navigating a Competitive and Capital-Intensive Landscape

Tenaya does not operate in a vacuum. The cardiovascular gene therapy space is becoming increasingly active, with large pharmaceutical firms and specialized biotechs all vying to bring breakthrough treatments to market. In this environment, attracting top-tier executive talent is as much a competitive advantage as securing a patent.

By bringing Hyllengren on board, Tenaya sends a strong message to the market that it is serious about its financial strategy and its future. His decision to join the company can also be seen as a vote of confidence in its science and leadership. “I am thrilled to join Tenaya at such a vital time in its evolution,” Hyllengren commented, citing the company’s promising clinical data and deep discovery expertise as key reasons for his enthusiasm.

For a company with a market valuation that has faced pressure, a seasoned CFO can bring a renewed focus on investor relations and capital strategy. Hyllengren's appointment is a clear effort to pair Tenaya’s promising scientific engine with the financial horsepower required to cross the finish line, transforming genetic insights into tangible, life-saving medicines for patients with heart disease.